$570,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Ensuring Patient Access to Critical Breakthrough Products Act of 2023(H.R. 1691) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. 2025 Reauthorization of the SUPPORT for Patients and Communities Act (Public Law 115-271)- Advocacy for reauthorization of the SUPPORT Act, specifically for FDA approved alternative treatments for Chronic Pain, and medical devices role to address the opioid epidemic. CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET) - advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization. Implementation of the Food and Drug Omnibus Reform Act of 2022 (Public Law 117-328) - advocacy efforts on Medical Device User Fee Amendments (MDUFA) reauthorization, riders, and device shortages. Implementation of the Chips and Science Act (Public Law 117-167) - advocacy to establish a $29 billion fund at the National Science Foundation to fund research in the areas of AI and medical technology. Additional efforts on semiconductor and raw materials shortages, device shortage reporting, resilient supply chain, domestic incentives and Buy America proposals. 21st Century Cures Act 2.0 (CURES 2.0) - legislation to advance medical research and to foster a new era of medical innovation and prepare for future pandemics and promote health equity. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) (Public Law 109-417) - advocacy on risk mitigation plans and voluntary shortage reporting related to medical device supply chains. FY2025 Impatient Payment System Proposed Rule: Changes to the New Tech Add-On Payment (NTAP) application and acceptance process, including clarification of deadlines and eligibility requirements. Support passage of the Radiation Oncology Case Rate (ROCR) Value Based Payment Program Act of 2025 - Senate (S. 1031) & (H.R. 2120). This legislation would increase access to patient care, enhance the quality of cancer treatments, encourage innovation, reduce disparities for rural and underserved patients, and lower patient costs by saving Medicare about $200 million over 10 years. Medical device procurement and supply chain resiliency. Ensuring VHA patient access to Med Tech as VHA manages supply chain and upgrades its medical surgery and prosthetics procurement contracting. Pain management - working to increase veteran access to multidisciplinary and multimodal pain management to provide for effective non-opioid treatment alternatives. OECD 2 Pillar Framework Implementation - International tax provisions specifically regarding the global minimum tax, including the Defending American Jobs Act (H.R. 591) and the Unfair Tax Prevention Act (H.R.2423), legislation regarding extraterritorial taxation. H.R. 1990 American Innovation and R&D Competitiveness Act of 2025. H.R. 1 (and Senate Amendment 2360) The One Big Beautiful Bill Act- Maintaining the International Tax regime as established in the 2017 TCJA legislation. Policies include proposed changes to GILTI, specifically Country by Country Reporting, the Section 250 deduction, Roundtripping, Section 899, and to return to pre-2022 R&D expensing rules. Supply Chain - advocacy efforts on topics that could potentially impact the medical device supply chain such as decisions made by the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party, outbound investments, raw materials, components, export controls, and shortage/supply chain resiliency reporting regulations. EPA Rulemaking Restricting Ethylene Oxide (ETO) - Proposed rulemaking to place more-stringent limits on emissions and institute new monitoring requirements for ethylene oxide (ETO). Advocacy efforts include educating lawmakers on the importance of ETO in the sterilization of medical devices and potential shortages of sterile medical devices if EPA's proposed changes are enacted. Senate Armed Services Committees Draft National Defense Authorization Act (NDAA) of Fiscal Year 2026 Warrior Right to Repair Act of 2025 Proposal- If enacted this legislation would enforce an expansive right to repair (RTR) policy on any businesses that contract with the Department of Defense. We are engaging in advocacy efforts towards the removal of this provision from the Senate bill in conference and to keep it out of the House Armed Services Committees NDAA legislation. We are educating lawmakers on the critical role of the Food and Drug Administration in maintaining product safety and effectiveness throughout the device lifecycle, and the potential risks associated with third-party servicing of medical technologies."
You can find more data on corporate lobbying on Quiver Quantitative.
BSX Congressional Stock Trading
Members of Congress have traded $BSX stock 10 times in the past 6 months. Of those trades, 2 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 6 times. They made 0 purchases and 6 sales worth up to $90,000 on 06/26, 06/11, 05/13, 04/28, 03/17, 02/24.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- SENATOR JOHN BOOZMAN purchased up to $15,000 on 02/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BSX Insider Trading Activity
BSX insiders have traded $BSX stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 5 sales selling 493,328 shares for an estimated $50,348,180.
- JOSEPH MICHAEL FITZGERALD (EVP & Group Pres, Cardiology) has made 0 purchases and 2 sales selling 106,372 shares for an estimated $11,147,945.
- DANIEL J. BRENNAN (EVP and CFO) has made 0 purchases and 4 sales selling 99,950 shares for an estimated $10,504,430.
- ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) has made 0 purchases and 3 sales selling 34,627 shares for an estimated $3,529,489.
- JOHN BRADLEY SORENSON (EVP, Global Operations) has made 0 purchases and 6 sales selling 24,650 shares for an estimated $2,586,989.
- JEFFREY B. MIRVISS (EVP&Pres, Periph Intervent) has made 0 purchases and 4 sales selling 21,895 shares for an estimated $2,294,072.
- VANCE R BROWN (SVP, GC and Corp. Secretary) has made 0 purchases and 4 sales selling 19,304 shares for an estimated $1,964,182.
- EDWARD J LUDWIG has made 0 purchases and 2 sales selling 16,000 shares for an estimated $1,684,182.
- ELLEN M ZANE sold 13,586 shares for an estimated $1,416,133
- EMILY WOODWORTH (SVP, Global Controller and CAO) sold 9,887 shares for an estimated $999,872
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BSX Hedge Fund Activity
We have seen 853 institutional investors add shares of BSX stock to their portfolio, and 613 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC removed 9,090,074 shares (-55.0%) from their portfolio in Q1 2025, for an estimated $917,006,665
- JPMORGAN CHASE & CO added 5,278,861 shares (+20.1%) to their portfolio in Q1 2025, for an estimated $532,531,497
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 4,568,703 shares (-20.5%) from their portfolio in Q1 2025, for an estimated $460,890,758
- BANK OF AMERICA CORP /DE/ added 4,078,325 shares (+14.8%) to their portfolio in Q1 2025, for an estimated $411,421,426
- FMR LLC removed 3,845,669 shares (-2.9%) from their portfolio in Q1 2025, for an estimated $387,951,088
- TWO SIGMA ADVISERS, LP added 3,450,700 shares (+456.9%) to their portfolio in Q1 2025, for an estimated $348,106,616
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 3,138,336 shares (-16.0%) from their portfolio in Q1 2025, for an estimated $316,595,335
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BSX Analyst Ratings
Wall Street analysts have issued reports on $BSX in the last several months. We have seen 14 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 06/16/2025
- Needham issued a "Buy" rating on 05/28/2025
- Citigroup issued a "Buy" rating on 05/22/2025
- Morgan Stanley issued a "Overweight" rating on 05/16/2025
- Barclays issued a "Overweight" rating on 04/25/2025
- Raymond James issued a "Strong Buy" rating on 04/24/2025
- RBC Capital issued a "Outperform" rating on 04/24/2025
To track analyst ratings and price targets for BSX, check out Quiver Quantitative's $BSX forecast page.
BSX Price Targets
Multiple analysts have issued price targets for $BSX recently. We have seen 14 analysts offer price targets for $BSX in the last 6 months, with a median target of $120.0.
Here are some recent targets:
- Mike Kratky from Leerink Partners set a target price of $118.0 on 06/16/2025
- Mike Matson from Needham set a target price of $115.0 on 05/28/2025
- Joanne Wuensch from Citigroup set a target price of $125.0 on 05/22/2025
- Patrick Wood from Morgan Stanley set a target price of $125.0 on 05/16/2025
- Matt Miksic from Barclays set a target price of $125.0 on 04/25/2025
- Jayson Bedford from Raymond James set a target price of $121.0 on 04/24/2025
- Shagun Singh from RBC Capital set a target price of $120.0 on 04/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
